A webinar series that explains how the new MoPath codes were created, how laboratories were able to influence the rate-setting process, and the outcome.
A summary of the outcome of the recently concluded Medicare gapfilling process for 114 new molecular pathology (MoPath) codes that were implemented in 2013. This presentation addresses the final 2013 regional rates for these codes, as well as the implications for national payment rates in 2014.
Learn about the latest developments in MoPath rate setting, how to participate in the rate setting process to ensure appropriate reimbursement for future molecular diagnostic tests, and how and when to respond to the current rate proposals.
A four-part webinar series intended to educate laboratory providers on the new Molecular Pathology (MoPath) codes for 2013 and how labs can influence sustainable reimbursement for molecular diagnostic services moving forward.
Understanding Reimbursement Implications for 2013
Influencing the Rate Setting Process
Obtaining Reimbursement for Cystic Fibrosis Genetic Testing
Obtaining Reimbursement for Cytogenomic Testing
|Tuesday, February 12
9 am PT
Join us for this introductory webinar to learn about the new MoPath codes, understand Medicare’s rate setting process and the implications for Medicaid and private payer reimbursements, and gain insight into how physicians bill for molecular diagnostic tests.
|Thursday, February 14
9 am PT
Learn how you can get involved and influence the rate-setting process, including how to influence accurate and sustainable reimbursement, the timeline of critical communications, and best practices for engaging payers.
|Tuesday, February 19
9 am PT
A review of the coverage landscape for cystic fibrosis (CF) testing, coding options for CF testing, and ways to develop detailed costing analysis for your test that will support favorable rate setting.
|Thursday, February 21
9 am PT
A review of the coverage landscape for cytogenomic testing, coding options for cytogenomic testing, and ways to develop detailed costing analysis for your test that will support favorable rate setting.
|View WebexGet PDF||View WebexGet PDF||View WebexGet PDF||View WebexGet PDF|
Illumina is providing this review of the molecular pathology reimbursement landscape in collaboration with Quorum Consulting for educational purposes only. The content should not be considered legal advice. For official ruling on the MoPath codes readers should consult CMS, the AMA, and other sources as appropriate.